Voyager Therapeutics, Inc. (VYGR) stock
VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3058% below fair value
$1.67+0.15 (+9.87%)
Close on Nov 18, 2026Market cap $102.90MP/E –Yield –
Voyager Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Voyager Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $34.46M, down 19.1% year over year. For fiscal 2025 it was $40.37M, down 49.5% from the year before. Over ten years it grew 8.8% a year on average. The highest annual figure on record is $250.01M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.37M | -49.5% |
| FY2024 | Dec 31, 2024 | $80.00M | -68.0% |
| FY2023 | Dec 31, 2023 | $250.01M | +511.2% |
| FY2022 | Dec 31, 2022 | $40.91M | +9.3% |
| FY2021 | Dec 31, 2021 | $37.42M | -78.1% |
| FY2020 | Dec 31, 2020 | $171.13M | +63.9% |
| FY2019 | Dec 31, 2019 | $104.39M | +1270.1% |
| FY2018 | Dec 31, 2018 | $7.62M | -24.8% |
| FY2017 | Dec 31, 2017 | $10.14M | -28.7% |
| FY2016 | Dec 31, 2016 | $14.22M | -18.0% |
| FY2015 | Dec 31, 2015 | $17.33M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.17M | -39.1% |
| Q1 FY2026 | Mar 31, 2026 | $2.59M | -59.9% |
| Q4 FY2025 | Dec 31, 2025 | $15.34M | +144.3% |
| Q3 FY2025 | Sep 30, 2025 | $13.37M | -45.7% |
| Q2 FY2025 | Jun 30, 2025 | $5.20M | -82.4% |
| Q1 FY2025 | Mar 31, 2025 | $6.47M | -66.8% |
| Q4 FY2024 | Dec 31, 2024 | $6.28M | -93.0% |
| Q3 FY2024 | Sep 30, 2024 | $24.63M | +433.8% |
| Q2 FY2024 | Jun 30, 2024 | $29.58M | +509.5% |
| Q1 FY2024 | Mar 31, 2024 | $19.52M | -87.0% |
| Q4 FY2023 | Dec 31, 2023 | $90.06M | +119.2% |
| Q3 FY2023 | Sep 30, 2023 | $4.61M | +548.0% |
| Q2 FY2023 | Jun 30, 2023 | $4.85M | +637.5% |
| Q1 FY2023 | Mar 31, 2023 | $150.48M | +436.0% |
| Q3 FY2022 | Sep 30, 2022 | $41.09M | +2672.3% |
| Q2 FY2022 | Jun 30, 2022 | $712.00K | -47.5% |
| Q1 FY2022 | Mar 31, 2022 | $658.00K | -89.9% |
| Q4 FY2021 | Dec 31, 2021 | $28.07M | +329.4% |
| Q3 FY2021 | Sep 30, 2021 | $1.48M | -98.7% |
| Q2 FY2021 | Jun 30, 2021 | $1.36M | -95.3% |
| Q1 FY2021 | Mar 31, 2021 | $6.50M | -64.0% |
| Q4 FY2020 | Dec 31, 2020 | $6.54M | -80.0% |
| Q3 FY2020 | Sep 30, 2020 | $117.84M | +476.7% |
| Q2 FY2020 | Jun 30, 2020 | $28.68M | -37.8% |
| Q1 FY2020 | Mar 31, 2020 | $18.07M | +247.6% |
| Q4 FY2019 | Dec 31, 2019 | $32.67M | +1527.2% |
| Q3 FY2019 | Sep 30, 2019 | $20.43M | +875.8% |
| Q2 FY2019 | Jun 30, 2019 | $46.09M | +1689.8% |
| Q1 FY2019 | Mar 31, 2019 | $5.20M | +451.7% |
| Q4 FY2018 | Dec 31, 2018 | $2.01M | -68.4% |
| Q3 FY2018 | Sep 30, 2018 | $2.09M | +82.4% |
| Q2 FY2018 | Jun 30, 2018 | $2.58M | +118.8% |
| Q1 FY2018 | Mar 31, 2018 | $942.00K | -35.7% |
| Q4 FY2017 | Dec 31, 2017 | $6.35M | +168.7% |
| Q3 FY2017 | Sep 30, 2017 | $1.15M | -65.3% |
| Q2 FY2017 | Jun 30, 2017 | $1.18M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.46M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.36M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.31M | – |
See a number that looks wrong?